Online inquiry

IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3418MR)

This product GTTS-WQ3418MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ALB gene. The antibody can be applied in Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213
UniProt ID P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3418MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13559MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ8660MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ2939MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ5060MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ9729MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ13687MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ4939MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ7578MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW